Bills, bills, bills

Expanding fintech company bets on Houston for second office

California-based Bill.com is opening its second office in Houston. Photo via Bill.com

Usually, getting stuck with the bill isn't a good situation to be in, but this is different. Houston just scored the second office of Bill.com, a Palo Alto, Calif.-based business software company. The company decided on Houston because of what the city has to offer both the business and its employees.

"We conducted an extensive national search to select our first location outside the San Francisco Bay Area," says René Lacerte, CEO of Bill.com, in a release from the Greater Houston Partnership. "We're growing at a high speed and it's critical to find the right mix of talent, quality of life and business-friendliness in our next office location. We found all this and more in Houston and are delighted the city can support our next phase of growth."

Planned to open this spring, Bill.com's Houston office will be located on the west side of town at the CityWest development, where it will occupy 25,000 square feet, per the release, and employ 125 people.

"The City of Houston is thrilled to welcome the Bill.com team," says Houston Mayor Sylvester Turner in the release. "We've always been a global and innovative city and the Bill.com announcement is another great example of Houston's building momentum as a leading digital tech hub. We offer a great place to live, work and grow a business, especially for startups and entrepreneurs."

Bill.com was founded in 2006 by René Lacerte and has raised over $259 million in funding. The software-as-a-service company has over 3 million members, according to Bill.com, and processes $60 billion in payments annually.

The Greater Houston Partnership was instrumental in bringing the second Bill.com office to town.

"Houston has always been at the cutting edge of technology — we put a person on the moon and created the first artificial heart, and we continue to build on that legacy," says Susan Davenport, the Greater Houston Partnership's chief economic development officer. "We've been working hard over the last couple of years to develop our community as a hub for digital tech, and the Bill.com expansion here is a validation and confirmation that we've made great progress."

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News